{
  "id": 20120315,
  "updated": "2019-02-18T19:03:06Z",
  "additionalIndexing": "2841",
  "affairType": {
    "abbreviation": "Iv. ct.",
    "id": 3,
    "name": "Initiative déposée par un canton"
  },
  "author": {
    "canton": {
      "abbreviation": "BS",
      "id": 12,
      "name": "Bâle-Ville"
    },
    "type": "author"
  },
  "deposit": {
    "date": "2012-08-08T00:00:00Z",
    "legislativePeriod": 49,
    "session": "4905"
  },
  "descriptors": [
    {
      "key": "L03K010503",
      "name": "pharmazeutische Industrie",
      "type": 1
    },
    {
      "key": "L04K01050301",
      "name": "pharmazeutisches Erzeugnis",
      "type": 1
    },
    {
      "key": "L04K11050302",
      "name": "Preisfestsetzung",
      "type": 1
    },
    {
      "key": "L04K01050502",
      "name": "Arzneimittelrecht",
      "type": 1
    },
    {
      "key": "L04K16020101",
      "name": "angewandte Forschung",
      "type": 1
    },
    {
      "key": "L05K0704030111",
      "name": "Wirtschaftsstandort Schweiz",
      "type": 2
    },
    {
      "key": "L04K16020106",
      "name": "Industrieforschung",
      "type": 2
    }
  ],
  "drafts": [
    {
      "consultation": {
        "resolutions": [
          {
            "category": {
              "id": 3,
              "name": "Normal"
            },
            "council": {
              "abbreviation": "CE",
              "id": 2,
              "name": "Conseil des Etats",
              "type": "S"
            },
            "date": "2013-06-11T00:00:00Z",
            "text": "Refusé de donner suite",
            "type": 51
          },
          {
            "category": {
              "id": 3,
              "name": "Normal"
            },
            "council": {
              "abbreviation": "CN",
              "id": 1,
              "name": "Conseil national",
              "type": "N"
            },
            "date": "2013-09-16T00:00:00Z",
            "text": "Refusé de donner suite",
            "type": 51
          }
        ]
      },
      "federalCouncilProposal": {
      },
      "index": 0,
      "links": [

      ],
      "preConsultations": [
        {
          "committee": {
            "abbreviation": "CSSS-CN",
            "id": 6,
            "name": "Commission de la sécurité sociale et de la santé publique CN",
            "abbreviation1": "CSSS-CN",
            "abbreviation2": "CSSS",
            "committeeNumber": 6,
            "council": {
              "abbreviation": "CN",
              "id": 1,
              "name": "Conseil national",
              "type": "N"
            },
            "typeCode": 1
          },
          "date": "2012-08-08T00:00:00Z",
          "registrations": [
            {
              "correspondents": [

              ],
              "sessionId": "4910"
            }
          ],
          "treatmentCategory": "V"
        },
        {
          "committee": {
            "abbreviation": "CSSS-CE",
            "id": 19,
            "name": "Commission de la sécurité sociale et de la santé publique CE",
            "abbreviation1": "CSSS-CE",
            "abbreviation2": "CSSS",
            "committeeNumber": 19,
            "council": {
              "abbreviation": "CE",
              "id": 2,
              "name": "Conseil des Etats",
              "type": "S"
            },
            "typeCode": 1
          },
          "date": "2012-08-08T00:00:00Z",
          "registrations": [
            {
              "correspondents": [
                {
                  "council": {
                    "abbreviation": "CE",
                    "id": 2,
                    "name": "Conseil des Etats",
                    "type": "S"
                  },
                  "councillor": {
                    "code": 2380,
                    "gender": "f",
                    "id": 316,
                    "name": "Egerszegi-Obrist Christine",
                    "officialDenomination": "Egerszegi-Obrist"
                  },
                  "faction": {
                    "abbreviation": "Groupe RL",
                    "id": 1,
                    "name": "Groupe libéral-radical"
                  },
                  "language": "de"
                }
              ],
              "sessionId": "4909"
            }
          ]
        }
      ],
      "references": [

      ],
      "relatedDepartments": [

      ],
      "states": [
        {
          "date": "/Date(1344376800000+0200)/",
          "id": 24,
          "name": "Non encore traité au conseil"
        },
        {
          "date": "/Date(1370901600000+0200)/",
          "id": 3,
          "name": "Traité par le Conseil des Etats"
        },
        {
          "date": "/Date(1379282400000+0200)/",
          "id": 27,
          "name": "Liquidé"
        }
      ],
      "texts": [

      ]
    }
  ],
  "handling": {
    "date": "2013-09-16T00:00:00Z",
    "legislativePeriod": 49,
    "session": "4910"
  },
  "language": "fr",
  "priorityCouncils": [
    {
      "abbreviation": "CE",
      "id": 2,
      "name": "Conseil des Etats",
      "type": "S",
      "priority": 1
    }
  ],
  "relatedAffairs": [

  ],
  "roles": [
    {
      "canton": {
        "abbreviation": "BS",
        "id": 12,
        "name": "Bâle-Ville"
      },
      "type": "author"
    }
  ],
  "sequentialNumber": 122,
  "shortId": "12.315",
  "state": {
    "id": 27,
    "name": "Liquidé",
    "doneKey": "1",
    "newKey": 0
  },
  "texts": [
    {
      "type": {
        "id": 5,
        "name": "Texte déposé"
      },
      "value": "<p>Se fondant sur l'article 160 alinéa 1 de la Constitution fédérale, le canton de Bâle-Ville soumet à l'Assemblée fédérale l'initiative suivante:</p><p>L'Assemblée fédérale est chargée de modifier les bases légales régissant l'homologation des médicaments, la reconnaissance des contrôles effectués à l'étranger, la définition des prix et la protection de l'innovation, de manière à renforcer l'industrie des sciences de la vie, qui revêt une grande importance pour la Suisse. Il s'agira en particulier de remanier les dispositions concernant l'examen et l'homologation des médicaments ainsi que celles régissant la protection de l'innovation dans le domaine pharmaceutique, de sorte que la Suisse soit assurée de rester un lieu d'implantation attractif à long terme.</p>"
    },
    {
      "type": {
        "id": 1,
        "name": "Titre de l'objet"
      },
      "value": "Améliorer les conditions d'implantation des entreprises de recherche pharmaceutique"
    }
  ],
  "title": "Améliorer les conditions d'implantation des entreprises de recherche pharmaceutique"
}